AR049564A1 - Metodos para la evaluacion y tratamiento del cancer - Google Patents
Metodos para la evaluacion y tratamiento del cancerInfo
- Publication number
- AR049564A1 AR049564A1 ARP050102730A ARP050102730A AR049564A1 AR 049564 A1 AR049564 A1 AR 049564A1 AR P050102730 A ARP050102730 A AR P050102730A AR P050102730 A ARP050102730 A AR P050102730A AR 049564 A1 AR049564 A1 AR 049564A1
- Authority
- AR
- Argentina
- Prior art keywords
- patient
- fti
- treatment
- determined
- farnesyl transferase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
Métodos para el tratamiento de pacientes con cáncer y, preferentemente, con una malignidad hematologica, que incluyen analizar los perfiles de expresion génica y/o marcadores moleculares de un paciente para determinar la probabilidades de que el paciente responda al tratamiento con inhibidores de la farnesil transferasa (FTI) y, optativamente, otros agentes terapéuticos. Los métodos son, asimismo, para monitorear la terapia del paciente y para seleccionar un curso terapéutico. Se presentan los genes modulados en la respuesta al tratamiento con FTI y se los utiliza para la formulacion de los perfiles. Reivindicacion 1: Un método para determinar si un paciente ha de responder al tratamiento con un inhibidor de la farnesil transferasa (FTI) mediante el análisis de la presencia o expresion del oncogén LBC (SEC. ID. No. 2). Reivindicacion 27: Artículos para evaluar la eficacia del tratamiento de un paciente con un inhibidor de la farnesil transferasa (FTI) que comprende un medio con el cual se determinan los perfiles de expresion génica del paciente indicativos de la respuesta al FTI. Reivindicacion 39: El uso de un inhibidor de la farnesil transferasa (FTI) para la preparacion de un medicamento para tratar a un paciente en quien ya se ha determinado o está por determinarse que el oncogén LBC (SEC. ID. No. 2) está ausente o no se expresa. Reivindicacion 41: Un kit de diagnostico para analizar una muestra de un paciente, por lo cual se determina la presencia o expresion del oncogén LBC (SEC. ID. No. 2).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/883,436 US20050003422A1 (en) | 2003-07-01 | 2004-07-01 | Methods for assessing and treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
AR049564A1 true AR049564A1 (es) | 2006-08-16 |
Family
ID=35058443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050102730A AR049564A1 (es) | 2004-07-01 | 2005-06-30 | Metodos para la evaluacion y tratamiento del cancer |
Country Status (14)
Country | Link |
---|---|
US (1) | US20050003422A1 (es) |
EP (1) | EP1611890B1 (es) |
JP (1) | JP2006014739A (es) |
KR (1) | KR20060048684A (es) |
CN (1) | CN1721553A (es) |
AR (1) | AR049564A1 (es) |
AT (1) | ATE440604T1 (es) |
AU (1) | AU2005202520A1 (es) |
BR (1) | BRPI0502433A (es) |
CA (1) | CA2512493A1 (es) |
DE (1) | DE602005016189D1 (es) |
DK (1) | DK1611890T3 (es) |
MX (1) | MXPA05007207A (es) |
PT (1) | PT1611890E (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0503418A (pt) * | 2004-05-06 | 2006-04-11 | Johnson & Johnson | prognóstico para malignidade hematológica |
US20080090242A1 (en) * | 2006-09-29 | 2008-04-17 | Schering Corporation | Panel of biomarkers for prediction of fti efficacy |
CA2680909A1 (en) * | 2007-03-12 | 2008-09-18 | Veridex, Llc | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase |
US7932036B1 (en) | 2008-03-12 | 2011-04-26 | Veridex, Llc | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase |
CA2804937C (en) * | 2008-03-21 | 2013-11-19 | Bauer Hockey Corp. | Helmet for a hockey or lacrosse player |
PT3301446T (pt) * | 2009-02-11 | 2020-07-14 | Caris Mpi Inc | Perfilagem molecular de tumores |
EP2598874B1 (en) * | 2010-07-28 | 2018-10-24 | Janssen Diagnostics, LLC | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors |
US11559540B2 (en) | 2010-07-28 | 2023-01-24 | Janssen Pharmaceutica Nv | Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors |
US20190119758A1 (en) * | 2016-04-22 | 2019-04-25 | Kura Oncology, Inc. | Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors |
US10806730B2 (en) | 2017-08-07 | 2020-10-20 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
MY200746A (en) * | 2017-08-07 | 2024-01-13 | Kura Oncology Inc | Methods of treating cancer with farnesyltransferase inhibitors |
US20210231666A1 (en) * | 2018-06-06 | 2021-07-29 | La Jolla Institute For Immunology | Cd33 monocytes as a biomarker |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5221605A (en) | 1984-10-31 | 1993-06-22 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
US5310687A (en) | 1984-10-31 | 1994-05-10 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
US5238808A (en) | 1984-10-31 | 1993-08-24 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
TR199800825T2 (xx) | 1995-12-08 | 1998-08-21 | Janssen Pharmaceutica N.V. | Farnesil protein transferini inhibe eden (imidazol-5-il) metil-2-kinolinon t�revleri. |
US5874442A (en) | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
JP2001505548A (ja) | 1996-12-20 | 2001-04-24 | トヴァリシェストヴォ エス オグラニチェンノイ オトヴェトストヴェンノストジュ“タブジュファーム” | 凍結乾燥ハイドロクロライド−1β,10β−エポキシ−13−ジメチルアミノ−グアヤ−3(4)−エン−6,12−オリドの生成方法および装置 |
US6303654B1 (en) | 1998-03-12 | 2001-10-16 | Wisconsin Alumni Research Foundation | Acyclic monoterpenoid derivatives |
AU3316600A (en) * | 1999-02-22 | 2000-09-21 | Torben F. Orntoft | Gene expression in bladder tumors |
JO2361B1 (en) | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl |
KR20040065524A (ko) * | 2001-10-30 | 2004-07-22 | 오르토-클리니칼 다이아그노스틱스, 인코포레이티드 | 백혈병을 검사 및 치료하는 방법 |
US7473526B2 (en) * | 2002-03-29 | 2009-01-06 | Veridex, Llc | Breast cancer prognostic portfolio |
US20030224422A1 (en) * | 2002-04-08 | 2003-12-04 | St. Jude Children's Research Hospital, Inc. | Pre-and post therapy gene expression profiling to identify drug targets |
AU2004202980B2 (en) * | 2003-07-01 | 2009-05-07 | Veridex, Llc | Methods for assessing and treating leukemia |
-
2004
- 2004-07-01 US US10/883,436 patent/US20050003422A1/en not_active Abandoned
-
2005
- 2005-06-09 AU AU2005202520A patent/AU2005202520A1/en not_active Abandoned
- 2005-06-23 CA CA002512493A patent/CA2512493A1/en not_active Abandoned
- 2005-06-29 KR KR1020050056876A patent/KR20060048684A/ko not_active Application Discontinuation
- 2005-06-30 AR ARP050102730A patent/AR049564A1/es unknown
- 2005-06-30 MX MXPA05007207A patent/MXPA05007207A/es unknown
- 2005-06-30 JP JP2005192550A patent/JP2006014739A/ja not_active Abandoned
- 2005-07-01 BR BRPI0502433-1A patent/BRPI0502433A/pt not_active IP Right Cessation
- 2005-07-01 AT AT05254157T patent/ATE440604T1/de not_active IP Right Cessation
- 2005-07-01 DK DK05254157T patent/DK1611890T3/da active
- 2005-07-01 CN CNA2005100822115A patent/CN1721553A/zh active Pending
- 2005-07-01 EP EP05254157A patent/EP1611890B1/en not_active Not-in-force
- 2005-07-01 PT PT05254157T patent/PT1611890E/pt unknown
- 2005-07-01 DE DE602005016189T patent/DE602005016189D1/de active Active
Also Published As
Publication number | Publication date |
---|---|
DE602005016189D1 (de) | 2009-10-08 |
EP1611890A1 (en) | 2006-01-04 |
MXPA05007207A (es) | 2006-05-22 |
ATE440604T1 (de) | 2009-09-15 |
US20050003422A1 (en) | 2005-01-06 |
JP2006014739A (ja) | 2006-01-19 |
PT1611890E (pt) | 2009-09-29 |
DK1611890T3 (da) | 2009-11-16 |
KR20060048684A (ko) | 2006-05-18 |
EP1611890B1 (en) | 2009-08-26 |
CA2512493A1 (en) | 2006-01-01 |
BRPI0502433A (pt) | 2006-04-04 |
CN1721553A (zh) | 2006-01-18 |
AU2005202520A1 (en) | 2006-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR049564A1 (es) | Metodos para la evaluacion y tratamiento del cancer | |
AR048945A1 (es) | Pronostico para leucemia mieloide cronica | |
WO2012006589A3 (en) | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling | |
CR10147A (es) | "ligandos que tienen especificidad de enlace para vegf y/o egfr y métodos de uso de los mismos" | |
HUP0302332A2 (hu) | Génkimutatási eljárás ErbB-antagonistával végzett rákterápiára adott hatékony reakció valószínûségének növelésére | |
MXPA05005923A (es) | Metodos para la identificacion, valoracion y tratamiento de pacientes con terapia para la inhibicion de la proteasoma. | |
ATE353974T1 (de) | Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs | |
CR8181A (es) | Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer | |
WO2008146309A3 (en) | Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
WO2008088854A3 (en) | Genetic markers for predicting responsiveness to combination therapy | |
DE602004031405D1 (de) | Marker zur Prognose der Reaktion auf Therapie bzw. der Überlebensrate von Brustkrebspatienten | |
PA8537401A1 (es) | Diaminotiazoles | |
WO2005000091A3 (en) | Method and apparatus for detecting ischemia | |
PL1889920T3 (pl) | Sposób identyfikacji związków do terapii antynowotworowej in vitro | |
TW200636076A (en) | Method for measuring resistance or sensitivity to docetaxel | |
CY1113403T1 (el) | Νεος βιοδεικτης για την παρακολουθηση της εξελιξης των νοσων και την εκτιμηση της αποτελεσματικοτητας των θεραπειων | |
AR032917A1 (es) | Metodo para determinar la expresion de genes de dihidropirimidina deshidrogenasa | |
ATE454468T1 (de) | Nachweis der instabilität von mikrosatelliten und verwendung davon bei der tumordiagnose | |
MXPA06014175A (es) | Diagnostico o pronostico del curso del cancer de mama. | |
HK1070921A1 (en) | Method for determining the expression level of glutathione-s-transferase pi | |
BRPI0515794A (pt) | processos para avaliar pacientes com leucemia mielóide aguda | |
ATE373725T1 (de) | Methoden zur feststellung von akute myeloischen leukämie | |
Akýsýk et al. | CD44 variant exons in leukemia and lymphoma | |
JP2005530518A5 (es) | ||
AR056125A1 (es) | Procedimiento para el diagnostico de tromboembolias y cardiopatias isquemicas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |